Emcure Pharmaceuticals Limited has issued a postal ballot notice dated March 24, 2026, seeking shareholder approval for the appointment of Mr. C S Muralidharan as an Independent Director. The company published newspaper advertisements on March 25, 2026, confirming the electronic dispatch of the postal ballot notice and has engaged MUFG Intime India Private Limited to provide e-voting facilities.

Proposed Director Appointment

The postal ballot seeks approval for the appointment of Mr. C S Muralidharan (DIN: 00014740 and IDDB Registration Number: IDDB-DI-202506-074680) as an Independent Director of the company. The appointment is proposed for a term of three consecutive years with effect from April 01, 2026, and he will not be liable to retire by rotation.

Director's Professional Background

Mr. Muralidharan brings extensive corporate experience to the board. He is a Cost & Management Accountant with a Master's degree in commerce and has completed the Executive Program in General Management from Booth School of Business, University of Chicago. His professional experience spans 40 years across hydro-carbon and pharmaceutical sectors.

His career includes senior leadership positions across multiple entities in India, Asia and Europe. He has previously worked with organizations including Indian Oil Corporation Limited, Ranbaxy Group, Lupin Limited, Matrix Laboratories Limited, Watson Group, and Sun Pharmaceutical Industries Limited where he served as Group Chief Financial Officer.

E-Voting Process and Timeline

The company has implemented a comprehensive e-voting process for the postal ballot, with specific timelines established for shareholder participation.

Newspaper Advertisement and Regulatory Compliance

Pursuant to Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company published newspaper advertisements on March 25, 2026, in "Financial Express" (English - all editions) and "Loksatta" (Marathi - Pune edition). The advertisements confirmed the completion of electronic dispatch of the postal ballot notice dated March 24, 2026.

The postal ballot notice complies with General Circular No. 03/2025 dated September 22, 2025, issued by the Ministry of Corporate Affairs and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The Board of Directors approved Mr. Muralidharan's appointment at its meeting held on March 09, 2026, based on the recommendation of the Nomination and Remuneration Committee.

Scrutinizer and Results Declaration

The company has appointed Ms. Ashwini Inamdar (Membership No. FCS 9409, CP No. 11226) and alternatively Mr. Atul Mehta (Membership No. FCS 5782, CP No. 2486), Partners of M/s. Mehta & Mehta, Practicing Company Secretaries, as Scrutinizers for conducting the postal ballot process. The results will be declared within two working days from the conclusion of e-voting and displayed on the company's website, stock exchange websites, and MUFG Intime's website.

Emcure Pharmaceuticals Limited has successfully completed its postal ballot voting process, with all three special resolutions for independent director re-appointments passed by the requisite majority. The pharmaceutical company announced the results on March 24, 2026, following a comprehensive remote e-voting process that concluded on March 20, 2026.

Regulatory Filing and Compliance

The company submitted its formal intimation to stock exchanges under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The filing confirmed that members approved the re-appointment of three independent directors through the postal ballot process, with all appointments taking effect as scheduled.

Director Re-appointment Details

The postal ballot process resulted in the successful re-appointment of three independent directors for their second terms. Each director brings specialized expertise to the board and has been confirmed as not debarred by SEBI or related to existing directors or key managerial personnel.

Voting Process and Results

The remote e-voting process was conducted from February 19 to March 20, 2026, under the supervision of scrutinizer Ashwini Inamdar from Mehta & Mehta, Company Secretaries. With 189,572,547 outstanding shares and 117,430 eligible shareholders, the voting demonstrated strong shareholder confidence in the board composition.

Resolution Performance Summary

All three resolutions achieved the required three-fourth majority as mandated under the Companies Act, 2013, and SEBI regulations. The promoter group showed unanimous support across all resolutions, while public institutional and non-institutional shareholders also demonstrated strong backing for the appointments.

Corporate Governance Compliance

The postal ballot was conducted in full compliance with Section 108 of the Companies Act, 2013, and Regulation 44 of SEBI Listing Regulations. Public notices were issued in Financial Express and Loksatta newspapers on February 18, 2026, ensuring transparency and regulatory adherence.

The company has uploaded the complete voting results and scrutinizer's report on its website at www.emcure.com and submitted all required documentation to NSE and BSE for regulatory compliance. Company Secretary Amruta Yangalwar signed the regulatory filing, confirming the completion of all procedural requirements.